Calidi Biotherapeutics (CLDI) Receivables - Net (2022 - 2025)

Calidi Biotherapeutics has reported Receivables - Net for 4 years, with the latest figure at $50000.0 in Q2 2025.

• For the quarter ending Q2 2025, Receivables - Net fell 72.38% year-over-year to $50000.0; the trailing twelve-month figure through Jun 2025 stood at $50000.0 (down 72.38% YoY), and the FY2023 full-year result was $1.4 million, up 160819.54% from the prior year.
• Receivables - Net for Q2 2025 stood at $50000.0, roughly flat from $50000.0 in the prior quarter.
• The five-year high for Receivables - Net was $1.4 million in Q4 2023, with the low at $870.0 in Q4 2022.
• Average Receivables - Net over 4 years is $273790.0, with a median of $50000.0 recorded in 2025.
• Year-over-year, Receivables - Net soared 156221.84% in 2023 and slumped 72.38% in 2025.
• Tracing CLDI's Receivables - Net over 4 years: stood at $870.0 in 2022, then soared by 156221.84% to $1.4 million in 2023, then slumped by 86.69% to $181000.0 in 2024, then tumbled by 72.38% to $50000.0 in 2025.
• The last three Receivables - Net figures came in at $50000.0 (Q2 2025), $50000.0 (Q1 2025), and $181000.0 (Q2 2024), per Business Quant data.

Peer Comparison